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Abstract
Purpose Positron emission tomography (PET) imaging
of brain amyloid load has been suggested as a core
biomarker for Alzheimers disease (AD). The aim of
this study was to test the feasibility of using PET imaging
with 18F-AV-45 (florbetapir) in a routine clinical environment
to differentiate between patients with mild to moderate AD
and mild cognitive impairment (MCI) from normal healthy
controls (HC).
Methods In this study, 46 subjects (20 men and 26 women,
mean age of 69.0±7.6 years), including 13 with AD, 12 with
MCI and 21 HC subjects, were enrolled from three academic
memory clinics. PET images were acquired over a 10-min
period 50 min after injection of florbetapir (mean ± SD of
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radioactivity injected, 259±57 MBq). PET images were
assessed visually by two individuals blinded to any clinical
information and quantitatively via the standard uptake value
ratio (SUVr) in the specific regions of interest, which were
defined in relation to the cerebellum as the reference region.
Results The mean values of SUVr were higher in AD patients
(median 1.20, Q1-Q3 1.16-1.30) than in HC subjects (median
1.05, Q1-Q3 1.04-1.08; p00.0001) in the overall cortex and all
cortical regions (precuneus, anterior and posterior cingulate,
and frontal median, temporal, parietal and occipital cortex).
The MCI subjects also showed a higher uptake of florbetapir
in the posterior cingulate cortex (median 1.06, Q1-Q3 0.97-
1.28) compared with HC subjects (median 0.95, Q1-Q3 0.82-
1.02; p00.03). Qualitative visual assessment of the PET scans
showed a sensitivity of 84.6% (95% CI 0.550.98) and a
specificity of 38.1% (95% CI 0.180.62) for discriminating
AD patients from HC subjects; however, the quantitative as-
sessment of the global cortex SUVr showed a sensitivity of
92.3% and specificity of 90.5% with a cut-off value of 1.122
(area under the curve 0.894).
Conclusion These preliminary results suggest that PETwith
florbetapir is a safe and suitable biomarker for AD that can
be used routinely in a clinical environment. However, the
low specificity of the visual PET scan assessment could be
improved by the use of specific training and automatic or
semiautomatic quantification tools.
Keywords 18F-AV-45 . Florbetapir . Alzheimers disease .
PET imaging . Brain imaging
Introduction
The use of positron emission tomography (PET) imaging with
probes that bind specifically to β-amyloid and tau aggregates
has received increased attention recently because this tech-
nique may provide an earlier diagnosis of Alzheimers disease
(AD). Currently, AD [1, 2] must reach the dementia stage, in
which cognitive and noncognitive symptoms significantly
alter activities of daily living, to be clinically diagnosed.
However, disease symptoms are considered a consequence
of the cumulative burden of brain alterations that may begin
to appear years before initial clinical manifestations [3, 4].
Consequently, the new AD diagnostic criteria suggest that the
diagnosis of "prodromal AD" (also called the AD predementia
stage) [5] or "MCI due toAD pathology" [6] should rely on in-
vivo biomarkers of amyloid pathology, such as PET imaging
that uses ligands of amyloid plaques and degenerative neuro-
fibrillary tangles. Among the candidate probes, 11C-labelled
tracers have been extensively studied. The PIB compound
(N-methyl-[11C]2-(4-methylaminophenyl)-6-hydroxybenzo-
thiazole), a derivative of thioflavin T, was the first to demon-
strate the ability to clearly distinguish AD patients from healthy
control (HC) subjects [7]. PET imaging with 11C-PIB has also
been used to efficiently differentiate patients with mild cogni-
tive impairment (MCI) who have converted to AD from non-
converters [8], and to estimate the decreased amyloid load in
patients treated with bapineuzumab [9]. Nevertheless, 11C-PIB
uptake is also increased in nondemented elderly subjects [10]
and shows a variable level of agreement with other bio-
markers, such as cerebrospinal fluid (CSF) dosage of Aβ
[11]. Another 11C-labelled, benzoxazole-derived compound,
11C-BF-227, has good neocortical uptake in AD patients [12]
and appears to be able to discriminate MCI converters from
nonconverters better than voxel-based morphometry
using magnetic resonance imaging (MRI) [13, 14]. How-
ever, the 20-min radioactive half-life of both 11C-PIB and
11C-BF-227 is a serious barrier to increasing the accessibility
of biomarkers for routine clinical purposes, as the use of these
markers is limited to centres with an on-site cyclotron.
Consequently, 18F-labelled amyloid ligands appear to be
the best alternative, as the 110-min half-life of 18F allows the
centralized production and locoregional delivery of com-
pounds, similar to other PET radiotracers, such as 18F-FDG.
Several clinical studies have been conducted with a new
naphthalene family compound, 2-(1-{6-[(2-18F-fluoroethyl)
(methyl)amino]-2-naphthyl}ethylidene)malononitrile (18F-
FDDNP). PETwith 18F-FDDNP has demonstrated the ability
to discriminate between HC subjects, MCI patients and AD
patients [15]. However, 18F-FDDNP has limitations because
of its low metabolic stability and its high white matter binding
[16]. More recently, the standard uptake value ratio (SUVr) of
18F-labelled PIB (18F-flutemetamol) was observed to be high-
ly correlated with the SUVr of its parent molecule, 11C-PIB
[17]. However, another family of 18F-labelled ligands derived
from stilbene has been developed, and two compounds be-
longing to this family (AV-1 and AV-45) display favourable
properties for brain amyloid PET imaging. 18F-AV1 (BAY-94-
9172, florbetaben) has brain kinetic characteristics appropriate
for clinical use. When studied 90 to 120 min after injection,
the level of cortical uptake clearly distinguished 15 AD
patients from 15 healthy elderly subjects [18]. A recent phase
II study has shown that the visual rating of PET scans with
florbetaben has sufficient sensitivity (80%) and specificity
(91%) to distinguish AD patients from HC subjects [19].
The last stilbene family derivative, 18F-AV-45 (florbeta-
pir) [20], also has strong affinity for amyloid proteins in AD
brain homogenates (ki 10±3.3 nM) and faster in vivo kinetics
[21]. The use of florbetapir in amyloid imaging has recently
been validated in an autopsy study [22], and its safety profile
allows clinical applications in brain imaging [23]. A pilot study
comparing 16 AD patients with 16 HC subjects confirmed that
florbetapir binds selectively to amyloid proteins enabling AD
patients to be distinguished from HC subjects, and has kinetics
that allow imaging sessions as short as 10 min 50 to 60 min or
60 to 70 min after injection [24]. More recently, a multicentre
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study conducted at 31 US research sites that included 82 elderly
HC subjects, 62 AD patients and 62 MCI patients reported that
both qualitative visual ratings and a continuous mean cortical
SUVr quantification show high sensitivity and specificity for
distinguishing AD patients from MCI patients and elderly HC
subjects [25]. These findings suggest that florbetapir is a useful
biomarker for distinguishing AD and MCI patients from HC
subjects. However, these results were derived from premar-
keting studies, and little is known about their possible
replication under "real life" conditions and everyday practice.
In the present study, our aim was to assess the feasibility of
using PET imaging with florbetapir in third-level clinical
settings to differentiate patients with mild to moderate AD or
MCI patients from normal HC subjects in three PET centres.
In addition, we assessed the safety of a florbetapir injection
immediately after injection and during the follow-up period.
Methods
Subjects
Patients consecutively referred to the three participating memory
clinics (from the university hospitals of Tours, Caen and Toulouse
in France) and who met the NINCDS-ADRDA criteria for prob-
able AD and DSM-IV criteria for Alzheimers type dementia or
diagnostic criteria for amnestic MCI [26, 27] were allowed to
participate. All participants had to be at least 55 years of age, able
to speak French fluently, have completed at least 7 years of
education and have neither unstable somatic disease nor psychi-
atric comorbidities. HC subjects were recruited through a com-
munity advertisement and investigated in the same clinical
settings. AD patients were required to have a mini-mental state
examination (MMSE) score between 15 and 28. The diagnosis
was made considering the guidelines for global neuropsycholog-
ical testing [28] and an evaluation of verbal episodic memory
(Free and Cued Selective Reminding Test, FCSRT) [29], lan-
guage (verbal fluency, naming, comprehension) [30], gnosis [31],
praxis [32], visuospatial functions [33] and executive functions
[3436]. AD patients were excluded if they had any past or
current symptomatic treatment with acetylcholinesterase inhib-
itors or memantine or had participated in any experimental
study investigating A-β-lowering agents. MCI patients were
required to have a subjective memory complaint associated
with isolated impairment in episodic memory, assessed by a
free recall total score (based on the FCSRT) of less than 1.5 SD
from the means for their age and education level. Healthy
controls could not have any past history of or current major
depressive episodes and/or antidepressant treatment, cognitive
impairment in the diagnostic neuropsychological battery, mem-
ory complaints, or MRI brain scan abnormalities.
Vital signs and clinical status were checked before and after
scanning, and follow-up visits were systematically conducted
1 year after inclusion. Adverse events and serious adverse
events were assessed from the first administration of the tracer,
immediately after the scan and during the follow-up period.
According to French regulations and laws on biomedical
research, the study was approved by the ethics committee of
Tours (Comité de Protection des Personnes de la Région
Centre) and the French Agency for Safety and Security for
Medical Devices (Agence Française de Sécurité Sanitaire
des Produits de Santé, reference A81216-27). The study
was also registred in the ClinTrials database under N°
NCT01325259. Written informed consent was obtained
from all patients and HC subjects who entered the study
and from the next of kin of all participating patients. All
participants were asked to sign a specific consent form for
ApoE genotyping, according to French regulations. The
ethics committee approved the consent procedure.
A total of 46 subjects (20 men, 26 women, mean age 69.0±
7.6 years) were included in the study, including 13 AD
patients, 12MCI patients and 21HC subjects. The demograph-
ic and clinical characteristics of the 46 subjects are presented in
Table 1. ApoE genotyping was available for 38 subjects.
18F-AV-45 (florbetapir) synthesis
Florbetapir) was prepared by the nucleophilic substitution of
a tosylate precursor (E)-2-(2-(2-(5-(4-(tert-butoxycarbonyl
(methyl)amino)styryl)pyridin-2-yloxy)ethoxy)ethoxy)ethyl-
4-methylbenzenesulphonate (AV-105) provided by Avid
Radiopharmaceuticals (Philadelphia, PA) with a GMP cer-
tificate, on an automatic synthesizer according to previously
describedmethods [37]. The radiochemical purity and specific
activity were approximately 98% and 180±70 GBq/μmol
(mean ± SD values of 20 experiments), respectively. The
radiochemical yields were 4045%.
Image acquisition
MRI A brain MRI scan was performed in all subjects using
a 1.5-T imager in one centre (Tours), and 3-T imagers in the
other two centres (Caen, Toulouse). T2-weighted images
from each subject were used to investigate brain lesions.
PET Subjects were examined using whole-body hybrid
PET/CT scanners, including a Dual Gemini (Philips Medical
Systems), a Discovery RX VCT 64 (General Electric) and a
Biograph 6 TruePoint HiRez (Siemens Medical Solutions)
in Tours, Caen and Toulouse, respectively. All tomographs
operated in 3-D detection mode. For the three centres, the
acquisition data were processed by adapting the reconstruc-
tion parameters to those of the tomograph with the lowest
spatial resolution (Dual Philips GEMINI) to ensure that the
images could be matched. All PET sinograms were recon-
structed with a 3-D iterative algorithm, with corrections for
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randomness, scatter, photon attenuation and decay, which
produced images with an isotropic voxel of 2×2×2 mm and
a spatial resolution of approximately 5-mm full-width at a
half-maximum at the field of view centre. The acquisition
data were processed using the standard package provided
with each acquisition system. All cerebral emission scans
began 50 min after a mean injection of 4 MBq/kg weight of
florbetapir (mean ± SD injected radioactivity 259±
57 MBq). For each subject, two 10-min frames were ac-
quired to ensure movement-free image acquisition, but
only the first frame was qualitatively and quantitatively
analysed.
Image analysis
The florbetapir PET images were coregistered to the florbe-
tapir template proposed by Wong et al. [24] in the Talairach
space using PMOD v3.1 (PMOD Technologies) with a
mutual information similarity function. Standardized uptake
values (SUVs) were obtained by normalizing the tissue
concentration to the injected dose and body weight. The
regional-to-cerebellum SUVr was used for intersubject com-
parison [38] because the cerebellum has been reported to be
a region free of fibrillar amyloid plaques in AD brains [36].
Each regional SUVr value was expressed as the mean over
Table 1 Demographic and clinical characteristics of subjects included in the PET study
Characteristic AD patients MCI patients HC subjects p-value
Global AD vs.
HC
AD vs.
MCI
MCI vs.
HC
Gender (male/female, n) 4/9 7/5 9/12 0.380 – – –
Age (years)
n 13 12 21
Median (Q1, Q3) 68.0 (65.0, 74.0) 72.5 (69.5, 81.8) 66.0 (63.0, 68.0) 0.023 – – –
Mean (SD) 67.8 (6.5) 75.0 (10.1) 66.2 (4.3)
MMSE
n 11 12 21
Median (Q1, Q3) 23.0 (21.0, 25.0) 26.5 (24.5, 27.3) 29.0 (29.0, 30.0) <0.0001 <0.0001 – 0.002
Mean (SD) 23.0 (3.6) 25.9 (2.9) 29.0 (1.3)
MATTIS
n 11 12 21
Median (Q1, Q3) 126.0 (112.5, 129.5) 125.0 (119.3, 137.5) 143.0 (142.0, 144.0) <0.0001 <0.0001 – <0.0001
Mean (SD) 119.9 (14.6) 126.7 (11.0) 142.8 (1.4)
FCRST immediate free recall
n 11 12 21
Median (Q1, Q3) 10.0 (6.5, 14.0) 15.0 (14.0, 16.0) 16.0 (16.0, 16.0) <0.0001 <0.0001 0.010 0.010
Mean (SD) 10.0 (4.6) 14.3 (2.6) 15.7 (0.6)
FCRST immediate free and cued recall
n 10 12 21
Median (Q1, Q3) 17.0 (16.0, 26.5) 30.0 (20.8, 36.3) 47.0 (46.0, 48.0) <0.0001 <0.0001 – <0.0001
Mean (SD) 21.2 (11.4) 27.4 (13.8) 46.2 (2.7)
FCRST delayed free recall
n 8 11 14
Median (Q1, Q3) 2.5 (0.0, 9.5) 6.0 (0.5, 12.0) 13.0 (12.3, 14.0) 0.019 – – –
Mean (SD) 5.4 (6.7) 8.3 (9.3) 13.1 (1.9)
FCRST delayed free and cued recall
n 8 10 12
Median (Q1, Q3) 9.5 (2.5, 11.3) 9.0 (3.3, 12.0) 16.0 (16.0, 16.0) 0.002 0.004 – 0.003
Mean (SD) 7.8 (5.8) 7.9 (6.0) 14.7 (4.6)
ApoE genotype
n 10 9 19
ε4 carrier, n (%) 7 (70) 6 (67) 8 (42) 0.332 – – –
ε4 non carrier, n (%) 3 (30) 3 (33) 11 (58)
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the region of interest (ROI) and as the mean of the left and
right corresponding regions. To define the ROIs for analy-
sis, the grey and white matter, CSF and skull were identified
in the MR images of ten healthy subjects. ROIs were created
in the following 13 regions: precuneus, anterior cingulate,
posterior cingulate, frontal, temporal, parietal, occipital, hip-
pocampus, centrum semiovale, anterior putamen, posterior
putamen, caudate nucleus and pons.
Florbetapir PET images were also visually assessed by
two independent raters, who were nuclear medicine special-
ists and blinded to all clinical and diagnostic information.
The raters used a binary scale to classify each scan as 0 (no
significant florbetapir cortical uptake) and 1 (significant
florbetapir cortical uptake). Prior to this assessment, the
raters underwent a half-day training session on a training
set provided by AVID pharmaceuticals. The visual rating
was re-run by the two raters until they reached full agreement
for each discrepant case.
Statistical analysis
Descriptive statistics and tests were separately computed for
the AD, MCI and control subjects. The chi-squared test and
Fishers exact test were applied to assess differences in gender
or in ApoE ε4 genotype between groups and visual rating
categories. To compare the distributions of the continuous
Fig. 1 Representative axial,
sagittal and coronal
florbetapir-negative images of a
HC subject (a) and a MCI
patient (b), and
florbetapir-positive images of a
MCI patient (c) and an AD
patient (d)
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variables between groups, including SUVr, the Kruskal-Wallis
rank sum test was used. When significant global p-values
were obtained, pair-wise comparisons between the three
groups were performed using the Wilcoxon rank sum test,
and p-values were adjusted for multiple comparisons using the
false discovery rate method. All tests were two-sided. Mann-
Whitney tests were performed to compare the SUVr between
the two ApoE statuses in each group. The significance level
was set at p<0.05. The sensitivity and specificity of the visual
rating (PET-positive vs. PET-negative) were determined using
the clinical diagnosis as the gold standard. Inter-rater agreement
of the visual assessments was estimated by calculating Cohens
kappa (κ) and its 95% confidence interval (95% CI). A ROC
curve analysis allowed us to study the diagnostic power of the
cortex global ROI SUVr against clinical diagnoses, and the area
under the curve was calculated. The sensitivity and specificity
were also calculated at the optimal cut-off point. Statistical
analyses were performed using R software version 2.12.2 [38].
Results
Overall, the PET scan procedures were well tolerated, and
no serious adverse events were reported during the immedi-
ate follow-up period. At the 1-year follow-up, one patient
had bladder cancer, and another was hospitalized for a
ruptured aortic aneurysm. Both were considered serious
adverse events without evidence of a causal relationship
with the protocol procedures.
Visual analysis
Agreement analysis between the two raters yielded a κ value
of 0.71 (95% CI 0.500.93), which indicates substantial
agreement. Compared with the initial clinical diagnosis,
the visual PET scan rating classified 11 of the 13 AD
patients (85%) and 13 of the 21 HC subjects (60%) as
positive. A calculation of the visual sensitivity and specific-
ity compared with the clinical diagnosis yielded values of
84.6% (95% CI 0.550.98) and 38.1% (95% CI 0.180.62),
respectively. Among the MCI subjects, six were assigned to
the positive category and six to the negative category. Axial,
sagittal and coronal section slices of representative positive
AD and MCI patient scans and negative MCI and HC
patient scans are shown in Fig. 1. As shown in Table 2,
being an ApoE genotype carrier and uptake in the global
cortical ROI were the factors most significantly associated
with a positive PET visual assessment.
Quantitative analysis
Descriptive statistics and tests of ROI-to-cerebellum
SUVr for AD patients, MCI patients and HC subjects
are presented in Table 3. The mean values of SUVr were
significantly higher in AD patients than in HC subjects
in the overall cortex and most cortical regions (i.e. the
precuneus, anterior and posterior cingulate, temporal and
frontal median regions) (Fig. 2). Moreover, significant
differences were also observed between AD and MCI
patients in the precuneus (p00.045), posterior cingulate
(p00.030) and frontal median (p00.045) regions. Signif-
icantly higher florbetapir uptake in the posterior cingu-
late region was also found in MCI patients than in HC
subjects (p00.030). The ROC curve analysis showed the best
sensitivity (92.3%) and specificity (90.5%) values with a cut-
off value of 1.122 (area under the curve 0.894). As shown in
Table 4, florbetapir uptake among AD patients was signifi-
cantly higher in ApoE carriers than in non-carriers in the
precuneus, anterior cingulate, posterior cingulate, frontal me-
dian and temporal cortical regions, and amongMCI patients in
the anterior cingulate, posterior cingulate and frontal median
cortical regions.
Discussion
Our results indicate that PET with florbetapir is suitable for
routine use to improve the accuracy of AD diagnosis in
Table 2 Age, ApoE genotype, cortical ROI and FCRST free immedi-
ate recall scores according to visual rating
Visual rating p-value
0 1
Age (years)
n 16 30
Median (Q1, Q3) 70.5 (64.8, 74.5) 68.0 (63.3, 71.5) 0.272
Mean (SD) 71.2 (9.4) 67.8 (6.4)
ApoE genotype, n (%)
n 13 25
ε4 carrier 2 (15) 19 (76) 0.0004
ε4 non-carrier 11 (85) 6 (24)
Global cortical ROI
n 16 30
Median (Q1, Q3) 1.03 (1.01, 1.08) 1.14 (1.06, 1.27) 0.0007
Mean (SD) 1.04 (0.07) 1.18 (0.15)
FCRST immediate free recall
n 16 28
Median (Q1, Q3) 15.0 (14.8, 16.0) 15.0 (13.5, 16.0) 0.756
Mean (SD) 14.6 (2.3) 13.5 (4.0)
Clinical diagnosis, n (%)
AD 2 (12) 11 (37)
MCI 6 (38) 6 (20) 0.183
HC 8 (50) 13 (43)
626 Eur J Nucl Med Mol Imaging (2012) 39:621631
clinical settings, such as memory clinics, with acceptable
tolerability and sufficient reliability. In particular, the quan-
titative analyses showed a higher global SUVr and SUVr in
several cortical regions (precuneus, anterior and posterior
cingulate, frontal median, temporal, parietal and occipital
cortex) in AD patients than in HC subjects. Additionally, the
SUVr in the posterior cingulate and frontal median regions
was significantly higher in AD patients than in MCI
Table 3 SUVr values of cortical brain regions relative to the cerebellum
Region AD (n013) MCI (n012) HC (n021) p-value
Global AD vs. HC MCI vs. HC AD vs. MCI
Precuneus
Median (Q1, Q3) 1.47 (1.24-1.60) 1.10 (0.97-1.35) 1.04 (0.98-1.06) 0.0004 <0.0001 – 0.045
Mean (SD) 1.47 (0.32) 1.19 (0.30) 1.04 (0.16)
Anterior cingulate
Median (Q1, Q3) 1.42 (1.25-1.56) 1.09 (1.02-1.30) 0.98 (0.92-1.09) 0.001 0.0004 0.077 0.077
Mean (SD) 1.41 (0.30) 1.18 (0.31) 1.03 (0.21)
Posterior cingulate
Median (Q1, Q3) 1.33 (1.14-1.46) 1.06 (0.97-1.28) 0.95 (0.82-1.02) 0.0002 <0.0001 0.030 0.030
Mean (SD) 1.33 (0.25) 1.11 (0.20) 0.96 (0.21)
Frontal median
Median (Q1, Q3) 1.16 (1.10-1.33) 0.97 (0.87-1.14) 0.86 (0.83-0.93) 0.0008 0.004 – 0.045
Mean (SD) 1.21 (0.22) 1.01 (0.22) 0.90 (0.17)
Temporal
Median (Q1, Q3) 1.37 (1.27-1.43) 1.17 (1.07-1.34) 1.12 (1.08-1.15) 0.0008 0.0001 – 0.078
Mean (SD) 1.37 (0.18) 1.20 (0.17) 1.13 (0.10)
Parietal
Median (Q1, Q3) 1.23 (1.16-1.28) 1.08 (0.99-1.22) 1.06 (0.99-1.10) 0.016 – – –
Mean (SD) 1.21 (0.17) 1.09 (0.16) 1.06 (0.13)
Occipital
Median (Q1, Q3) 1.14 (1.08-1.23) 1.08 (1.02-1.17) 1.06 (1.03-1.11) 0.043 – – –
Mean (SD) 1.17 (0.14) 1.08 (0.11) 1.07 (0.06)
Cortex global ROI
Median (Q1, Q3) 1.20 (1.16-1.30) 1.09 (1.02-1.24) 1.05 (1.04-1.08) 0.001 0.0001 – 0.067
Mean (SD) 1.26 (0.15) 1.12 (0.15) 1.07 (0.09)
Hippocampus
Median (Q1, Q3) 0.88 (0.82-0.95) 0.90 (0.82-0.96) 0.88 (0.86-0.96) 0.967 – – –
Mean (SD) 0.89 (0.10) 0.89 (0.09) 0.89 (0.07)
Centrum semiovale
Median (Q1, Q3) 1.66 (1.56-1.81) 1.61 (1.49-1.73) 1.62 (1.55-1.76) 0.743 – – –
Mean (SD) 1.68 (0.18) 1.63 (0.17) 1.64 (0.13)
Posterior putamen
Median (Q1, Q3) 1.36 (1.21-1.40) 1.23 (1.13-1.30) 1.17 (1.11-1.19) 0.005 0.004 – –
Mean (SD) 1.31 (0.14) 1.23 (0.12) 1.16 (0.10)
Anterior putamen
Median (Q1, Q3) 1.44 (1.28-1.53) 1.20 (1.13-1.33) 1.14 (1.09-1.17) 0.0002 <0.0001 – 0.033
Mean (SD) 1.41 (0.17) 1.25 (0.18) 1.15 (0.14)
Caudate nucleus
Median (Q1, Q3) 0.83 (0.79-0.90) 0.86 (0.74-0.94) 0.90 (0.77-0.92) 0.869 – – –
Mean (SD) 0.85 (0.15) 0.85 (0.11) 0.86 (0.10)
Pons
Median (Q1, Q3) 1.49 (1.42-1.55) 1.48 (1.42-1.64) 1.52 (1.48-1.61) 0.380 – – –
Mean (SD) 1.49 (0.09) 1.52 (0.13) 1.54 (0.09)
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patients. To the best of our knowledge, the results of only
five clinical trials with 18F-labelled tracers that specifically
bind to brain amyloid plaques have been published to date
[15, 17, 19, 22, 25]. In all studies PET imaging with 18F-
labelled tracers was able to distinguish AD patients from HC
subjects, but only three [15, 17, 25] included MCI patients,
and the differences in SUVr between MCI patients and HC
subjects were only reported with an FDDNP tracer that
binds to both amyloid and tau proteins [15], which does
not appear to be the case with florbetapir [25]. The pattern of
florbetapir cortical uptake found in the present study is
remarkably similar to that found in previous studies con-
ducted by Wong et al. [24] and Clark et al. [22]. The pattern
also appears to be similar to those found with other amyloid-
labelling compounds, such as 11C-PIB [10] and its 18F-
flutemetamol-derived molecule [17], 11C -BF-227 [13],
18F-FDDNP [15] and 18F-BAY94-9172 [18, 19]. These
patterns closely match the neuropathological stages of AD
progression, which was strengthened by the high correlation
found between florbetapir PET imaging and autopsy results
[22]. Our results also indicate that there is high uptake of
florbetapir in the white matter (centrum semiovale) and the
striatum region (in particular, the putamen) to a similar degree
as with other 11C- [39, 40] and 18F-labelled compounds [17,
41, 42]. A high rate of amyloid deposition in the striatum has
been suggested to be more frequently associated with demen-
tia with Lewy bodies [43] or some early-onset variant of AD
associated with spastic paraparesis and a presenilin I (PSI)
gene mutation [44]; however, this finding has also been con-
sistently reported in PET imaging studies using amyloid
ligands in AD patients [17, 3942], and this high uptake level
in the striatum does not appear to be associated with decreased
glucose metabolism (as assessed by FDG PET), as it is in
other cortical areas [45].
The sensitivity (92,3%) and specificity (90,5%) values
provided a good quantitative assessment for the global cor-
tex ROI, with a cut-off value (1.12) lower than that calcu-
lated by Fleisher et al. (SUVr ≥1.17), but the mean global
SUVr (mean ± SD) values were also slightly lower in the
present series (AD patients 1.26 ± 0.15, MCI patients 1.12 ±
0.05, HC subjects 1.07 ± 0.09) than in the study by Fleisher et
al. (AD 1.39 ± 0.24, MCI 1.17 ± 0.27, HC 1.05 ± 0.16) [25].
However, the visual assessment less accurately distinguished
AD patients from HC subjects, demonstrating a specificity of
38.1%. There are at least two possible explanations for this
low specificity. First, the three different cameras between the
three participating sites required adaptation of the reconstruc-
tion parameters to those of the tomograph with the lowest
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Fig. 2 SUVr values for a set of volumes of interest in AD patients, MCI patients and HC subjects
spatial resolution (Dual Philips GEMINI) and this could have
led to some borderline positive scans being rated as negative
or conversely borderline negative scans being rated as positive.
Second, at least one HC subject was a clear outlier, with high
SUVr values and a positive visual rating. Interestingly, this HC
subject had a family history of AD and was a heterozygotic
ApoE4 gene carrier.
The association of the ApoE4 genotype with the likelihood
of having a positive florbetapir PET scan on visual rating is
another remarkable finding of this study. The association of the
ApoE genotype with a higher brain amyloid load has previous-
ly been documented in several PET imaging studies with PIB
[46, 47], florbetaben [19] and florbetapir [25]. Strikingly, the
ApoE genotype appears to increase florbetapir uptake levels in
several cortical regions in AD and MCI patients but not in HC
subjects, suggesting that the presence of ApoE could strengthen
or accelerate the level of amyloid deposition. Here the HC
subjects with a positive scan could have been at an early
preclinical stage of the disease in which criteria for MCI or
AD were not yet reached, and only the follow-up will confirm
its progression towards a full symptomatic feature of disease.
This study has several limitations. First, the sample size was
limited, but this work was initiated and conducted in only three
academic clinical settings independent of any premarketing
phase II studies now being conducted by industrial sponsors.
Another limitation was a possible selection bias, expressed by
the significantly older age in theMCI group than in the AD and
HC groups. Nevertheless, age did not differ between subjects
with positive and negative scans on visual rating (Table 2).
Moreover the MCI patients had a significantly older mean age
than the AD patients and HC subjects. It cannot be excluded
that this could have increased the mean values of florbetapir
uptake in favour of showing a significant difference in relation
to the HC subjects. Despite these limitations, the preliminary
results indicate that imaging techniques using 18F-labelled
compounds, such as florbetapir, can be easily conducted in
demented and predemented patients in clinical settings, such
as third-level memory clinics, and could become a routine
clinical procedure for patients with suspected AD. The low
specificity of the visual PET scan assessment is problematic,
but this could be significantly increased by improvements in
the spatial resolution of tomographs as well as by the use of
appropriate training programmes for raters, and by the devel-
opment of semiautomatic or automatic quantifications method
or software.
Conclusion
These preliminary results agree with previously reported
results obtained using other PET tracers that bind to brain
Table 4 SUVr values in the
cortical brain regions of ApoE
carriers and non-carriers
Region AD patients MCI patients HC subjects
Mean (SD) p-value Mean (SD) p-value Mean (SD) p-value
Precuneus
ε4 carrier 1.56 (0.29) 0.0167 1.37 (0.34) 0.0952 1.10 (0.24) 0.6574
ε4 non-carrier 1.09 (0.09) 0.99 (0.09) 1.00 (0.08)
Anterior cingulate
ε4 carrier 1.54 (0.28) 0.0167 1.38 (0.29) 0.0476 1.10 (0.30) 0.4421
ε4 non-carrier 1.03 (0.10) 0.89 (0.16) 0.97 (0.14)
Posterior cingulate
ε4 carrier 1.42 (0.22) 0.0167 1.27 (0.15) 0.0238 1.01 (0.32) 0.7780
ε4 non-carrier 1.02 (0.12) 0.90 (0.07) 0.92 (0.10)
Frontal median
ε4 carrier 1.30 (0.20) 0.0167 1.17 (0.17) 0.0238 0.98 (0.24) 0.1518
ε4 non-carrier 0.93 (0.13) 0.81 (0.11) 0.84 (0.09)
Temporal
ε4 carrier 1.42 (0.17) 0.0333 1.32 (0.14) 0.0952 1.15 (0.15) 0.4421
ε4 non-carrier 1.18 (0.09) 1.05 (0.10) 1.12 (0.06)
Parietal
ε4 carrier 1.22 (0.18) 0.6667 1.20 (0.12) 0.0476 1.08 (0.20) 0.9678
ε4 non-carrier 1.10 (0.23) 0.95 (0.09) 1.04 (0.07)
Occipital
ε4 carrier 1.18 (0.19) 0.6667 1.15 (0.11) 0.0952 1.08 (0.08) 0.7780
ε4 non-carrier 1.12 (0.08) 1.03 (0.09) 1.07 (0.05)
Cortex global ROI
ε4 carrier 1.29 (0.17) 0.1833 1.22 (0.13) 0.0952 1.09 (0.14) 0.5448
ε4 non-carrier 1.11 (0.09) 1.00 (0.09) 1.06 (0.05)
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amyloid plaques, and suggest that PET with florbetapir
could become a routine clinical procedure to improve the
reliability of AD diagnosis and the detection of typical or
atypical forms of predementia stages, such as amnestic MCI
and MCI associated with multidomain deficits or neuropsy-
chiatric symptoms (e.g. depression). More studies testing
the feasibility and tolerability of consecutive scans with
florbetapir are needed to better document the accuracy of
PET imaging with florbetapir in the AD diagnostic process
at the dementia or predementia stages. Comparisons (or
combinations) with other biomarkers, such as FDG PET,
MRI and CSF dosages of tau and protein, are also needed.
The clinical relevance of changes in quantity of brain amy-
loid over time, especially when disease-modifying treat-
ments are available, should also be assessed. Finally, the
reliability of visual rating of PET scans remains critical and
should be urgently addressed through the improvement in
spatial resolution of images, the use of semiquantitative meth-
ods and the support of appropriate training programmes for
nuclear medicine physicians.
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